Clindamycin, 150 mg capsules 16 pcs

Clindamycin is a drug from the group of antibiotics – lincosamides, has a broad spectrum of action, bacteriostatic, binds to the 50S ribosome subunit and inhibits protein synthesis in microorganisms.

Active against:

– Staphylococcus spp. (including penicillinase-producing Staphylococcus epidermidis).

– Streptococcus spp. (excluding Enterococcus spp.).

– Streptococcus pneumoniae.

– Anaerobic and microaerophilic gram-positive cocci (including Peptococcus spp. and Peptostreptococcus spp.).

– Corynebacterium diphtheriae.

– Clostridium perfringens.

– Clostridium tetani.

– Mycoplasma spp.

– Bacteroidesspp. (including Bacteroides fragilis and Bacteroides melaningenicus).

– Anaerobic Gram-positive, non-spore-forming bacilli (including Propionibacterium spp., Eubacterium spp., Actinomyces spp.).

Most strains of Clostridium perfringens are sensitive to clindamycin, but other species of clostridia (Clostridium sporogenes, Clostridium tertium) are resistant to the drug, so in infections caused by Clostridium spp.

In terms of mechanism of action and antimicrobial spectrum the drug is close to lincomycin (it is 2-10 times more active against some types of microorganisms, especially against bacteroides and non-sporulating anaerobes).

Indications

Infectious and inflammatory diseases caused by microorganisms sensitive to clindamycin:

– Upper respiratory tract infections and ENT infections

– Pharyngitis.

– Tonsillitis.

– Sinusitis.

– Otitis.

– Pneumonia, incl. aspiration

– Lung abscess.

– Empyema of the pleura.

– Bronchitis.

– Chlamydia.

– Endometritis.

– Vaginal infections.

– Tuboovarian inflammation.

– Infected wounds.

– Abscesses.

– Boils.

– Panaritium.

– Abdominal cavity:

– Peritonitis.

– Abscess.

Pharmacological effect

Clindamycin is a drug from the group of antibiotics – lincosamides, has a wide spectrum of action, is bacteriostatic, binds to the 50S ribosomal subunit and inhibits protein synthesis in microorganisms.

Active regarding:

– Staphylococcus spp. (including Staphylococcus epidermidis, producing penicillinase).

– Streptococcus spp. (excluding Enterococcus spp.).

– Streptococcus pneumoniae.

– Anaerobic and microaerophilic gram-positive cocci (including Peptococcus spp. and Peptostreptococcus spp.).

– Corynebacterium diphtheriae.

– Clostridium perfringens.

– Clostridium tetani.

– Mycoplasma spp.

– Bacteroidessp. (including Bacteroides fragilis and Bacteroides melaningenicus).

– Anaerobic gram-positive, non-spore-forming bacilli (including Propionibacterium spp., Eubacterium spp., Actinomyces spp.).

Most strains of Clostridium perfringens are sensitive to clindamycin, but other types of clostridia (Clostridium sporogenes, Clostridium tertium) are resistant to the drug, therefore, for infections caused by Clostridium spp., an antibiogram is recommended.

According to the mechanism of action and antimicrobial spectrum, it is close to lincomycin (against some types of microorganisms, especially against bacteroids and non-spore-forming anaerobes, it is 2-10 times more active).

Special instructions

– Use for liver dysfunction: Clindamycin is used with caution in patients with severe liver failure. Patients need to monitor liver function (liver enzymes).

– Use for impaired renal function: Clindamycin is used with caution in patients with severe renal failure.

Pseudomembranous colitis can appear both while taking clindamycin and 2-3 weeks after stopping treatment (3-15% of cases); manifested by diarrhea, leukocytosis, fever, abdominal pain (sometimes accompanied by the release of blood and mucus in the stool).

If these phenomena occur, in mild cases it is sufficient to discontinue treatment and use ion exchange resins (colestyramine, colestipol); in severe cases, replacement of the loss of fluid, electrolytes and protein, and the appointment of oral vancomycin or metronidazole are indicated.

You should not use medications that inhibit intestinal motility.

The safety of the drug in children under 3 years of age has not been established. With long-term therapy, children need periodic monitoring of their blood count and liver function.

When prescribing the drug in high doses, monitoring the concentration of clindamycin in plasma is necessary.

Active ingredient

Clindamycin

Composition

1 capsule contains:

Clindamycin (hydrochloride) 150 mg.

Excipients:

Corn starch,

Lactose monohydrate,

Talc,

Magnesium stearate.

Composition of the capsule body:

Azorubine dye (E122),

Diamond black dye (E151),

Gelatin.

Composition of the capsule cap:

Titanium dioxide (E171),

Quinoline yellow dye (E104),

Azorubine dye (E122),

Crimson dye Ponceau 4R (E124),

Diamond black dye (E151),

Gelatin.

Pregnancy

Contraindicated

Contraindications

– Myasthenia gravis.

– Bronchial asthma.

– Ulcerative colitis (history).

– Rare hereditary diseases, such as: galactose intolerance, lactase deficiency or glucose-galactose malabsorption (for capsules).

– Pregnancy.

– Lactation period.

– Children under 8 years of age for capsules (average child weight less than 25 kg).

– Increased sensitivity.

Use with caution in patients with:

– Severe liver and/or kidney failure.

– In elderly patients.

Interaction

Clindamycin enhances (mutually) the effect of rifampicin, aminoglycosides, streptomycin, gentamicin (especially in the treatment of osteomyelitis and the prevention of peritonitis after intestinal perforation).

Enhances the effect of competitive muscle relaxants, and also enhances muscle relaxation caused by n-cholinergic blockers.

Incompatible with ampicillin, barbiturates, aminophylline, calcium gluconate and magnesium sulfate.

Shows antagonism with erythromycin and chloramphenicol.

Simultaneous use with solutions containing B complex vitamins, aminoglycosides, and phenytoin is not recommended.

Concomitant use with antidiarrheal drugs increases the risk of developing pseudomembranous colitis.

When used simultaneously with opioid (narcotic) analgesics, the respiratory depression they cause may increase (up to apnea).

Overdose

– Symptoms: possible increased side effects.

– Treatment: symptomatic therapy, there is no specific antidote.

Hemodialysis and peritoneal dialysis are ineffective.

Storage conditions

Store at a temperature of 15-25 °C.

Keep out of the reach of children.

Do not use after expiration date.

Shelf life

3 years.

Manufacturer

Hemofarm A.D., Serbia